Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 19.12.2008 » Group B Streptococcus vaccine program licensed to Novartis - Intellectual property cross license agreement will allow Novartis to focus on vaccines ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. New Products 15.12.2008 » IXIARO® receives positive opinion from European Committee for Human Medicinal Products (CHMP) » First licensed vaccine against Japanese Encephalitis for travelers ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. New Products 12.12.2008 » Australian Drug Evaluation Committee (ADEC) has issued a positive recommendation for Intercell's first product, a new vaccine against Japanese Encephalitis » ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies Wien (euro adhoc) - Vienna (Austria), December 11, 2008 - Intercell AG (VSE: ICLL) announced today that the Company has been awarded the Scrip Award for Biotech Company of the Year at last night's ceremony at the London Hilton, Park Lane. The Scrip Awards are voted for by a panel of esteemed ...
» Presentation at ASTMH Meeting Underscores Safety and Immunogenicity of Vaccine in a Phase II trial in children » Additional Presentation Demonstrates Excellent Safety during 6-Month of Follow-Up across Phase III trials in adults » Marketing approval for the adult vaccine in the U.S., Europe and ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 10.12.2008 Vienna/Austria, December 10, 2008 - Intercell AG (VSE: ICLL) today announced the execution of a contract modification with the U.S. Department of Health and ...
» The World Economic Forum (WEF) awards innovators of the highest calibre, whose technologies have a deep impact on business and society » Intercell is the first Austrian company ever to be selected for this award » Vaccine innovator Intercell's technologies, its clear product focus and the company's solid financial situation qualified ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 9-month report 11.11.2008 Intercell successfully advanced parallel regulatory processes in all key markets for travelers and military personnel - Vaccine against Japanese Encephalitis ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 20.10.2008 » Intercell receives positive feedback from the US Food and Drug Administration (FDA) towards earliest possible product approval » Discussion on Japanese ...
» EUR 40 m further option fee paid by Novartis » Actual cash position more than EUR 200 m » Development of key products within the Novartis alliance progressing ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. cooperations Wien (euro adhoc) - Vienna (Austria), September 25, 2008 - Intercell AG ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 28.08.2008 Vienna (Austria), August 28, 2008 - Intercell AG (VSE: ICLL) today announced that its collaborator Merck & Co., Inc. has initiated a Phase II clinical trial of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 21.08.2008 Vienna (Austria), August 21, 2008 - Intercell AG (VSE: ICLL) announced that the Defense Logistics Agency (DLA), United States Department of Defense, has posted ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 6-month report 18.08.2008 » International approval processes for Japanese Encephalitis vaccine on schedule - Approvals of Intercell´s Japanese Encephalitis vaccine candidate in the US, ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 05.08.2008 » Intercell AG ("Intercell") closes the previously announced acquisition of Iomai Corporation ("Iomai") for a total consideration of 1,442,819 Intercell ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 01.08.2008 » Iomai shareholders voted in favour of the acquisition at the special shareholder meeting on August 1, 2008 » Important closing condition fulfilled - ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 11.07.2008 » Definitive proxy statement filed on July 10, 2008; Closing planned in first week of August; all preparations for full integration in place » Approval ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 19.06.2008 » Intercell submitted application to launch Japanese Encephalitis vaccine in Canada » Intercell confirms plans for market launch (Europe, US, Australia) ...
Announcement according to Para 82 Section 9 Austrian Stock Exchange Act in connection with Para 2 Section 1 and Para 3 Section 1 Publication Directive ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/Ordinary Shareholders' Meeting Wien (euro adhoc) - Vienna, June 13, 2008 - Intercell AG (Vienna Stock Exchange, ICLL) today announced that all ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 13.06.2008 » Further clinical trial for a seasonal flu vaccine containing Intercell´s adjuvant IC31® being initiated » Intercell will be entitled to receive EUR 2 m ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 05.06.2008 Vienna (Austria), June 5, 2008 - Intercell AG (VSE: ICLL) today announced that it has received notice that the U.S. Department of Justice and Federal Trade ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies/Announcement Wien (euro adhoc) - - 1. General 1.1 The shareholders´ meeting to be held on 13 June 2008 shall resolve on the grant of stock options to members of the supervisory ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 3-month report 13.05.2008 Intercell's investigational Japanese Encephalitis vaccine expected to obtain market approval in global traveler markets in 2008 - commercial production started » ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Company Information 12.05.2008 » Intercell AG ("Intercell") to acquire Iomai Corporation ("Iomai") in a fully recommended share/cash transaction for USD 6.60 per share of Iomai´s common ...
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies Wien (euro adhoc) - Vienna (Austria), April 30, 2008 - Following a successful year, Intercell AG (VSE, "ICLL") presents its final Annual Financial Report 2007. The illustrated Annual Report contains the audited consolidated financial statements according to IFRS and gives detailed ...
» Intercell's Hepatitis C vaccine candidate was awarded in the category of "Best New Therapeutic Vaccine" at the World Vaccine Congress » Intercell's therapeutic Hepatitis C vaccine successfully concluded Phase II clinical trials in February 2008 ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this announcement. companies Wien (euro adhoc) - Vienna ...
» Intercell and its partner institutions are awarded an EU grant for targeting research and novel treatments of fungal infections » Intercell further strengthens its fungal franchise by supporting the new Christian Doppler Laboratory PathoFUN focusing on the research of fungal pathogens ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for the content of this ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 15.04.2008 » Japanese Encephalitis (JE) Vaccine meets primary endpoints in Phase II trials in children » The results fully support Intercell's development plan for ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. quaterly report 03.03.2008 First profitable year in Intercell´s history - Clear growth in revenues and profitability expected for 2008 » EUR 5.0 m net profit and positive operating cash ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 29.02.2008 Vienna (Austria), February 29, 2008 - Intercell AG (VSE: ICLL) announced today the submission of application to register Intercell's investigational Japanese Encephalitis vaccine in ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. Research & Development 27.02.2008 » Intercell's adjuvant IC31® demonstrates very good safety and tolerability profile in first Phase I trial in Flu » Seroconversion and seroprotection ...